Evidence map›Paper›PMID 21727090›Full record

ArticleNucleic acids research2011

Predicting the functional impact of protein mutations: application to cancer genomics.

Boris Reva, Yevgeniy Antipin, Chris Sander

Open access · goldAbstract readValidation Study
In one paragraph

Article in Nucleic acids research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1,229 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1,229citing papers in PubMed, 4 pooled it
31.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1,229 citing papers in PubMed, 4 syntheses or guidelines pooled it, 2,107 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Clinical and genetic characteristics ofJournal of medical genetics · 2025
    Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Multi-omics analysis of HLTF context-dependent regulation across TCGA cohorts revealed its potential as new biomarker in tumour.Mammalian genome : official journal of the International Mammalian Genome Society · 2026
    Article
  16. Novel Compound Heterozygous Variants inJournal of clinical medicine · 2026
    Article
  17. Article
  18. Article
  19. Article
  20. Review

1,169 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Boris RevaComputational Biology Center, Memorial Sloan-Kettering Cancer Center, NY 10065, USA.
Yevgeniy Antipin
Chris Sander
Memorial Sloan Kettering Cancer Center · US

Funding

Functional consequences of cancer mutationsR01CA132744 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SANDER, CHRIS · 2009 to 2012
$2.8M
NCI NIH HHS R01 CA132744NCI NIH HHS R01 CA132744-02
6 · The paper itself

Abstract

As large-scale re-sequencing of genomes reveals many protein mutations, especially in human cancer tissues, prediction of their likely functional impact becomes important practical goal. Here, we introduce a new functional impact score (FIS) for amino acid residue changes using evolutionary conservation patterns. The information in these patterns is derived from aligned families and sub-families of sequence homologs within and between species using combinatorial entropy formalism. The score performs well on a large set of human protein mutations in separating disease-associated variants (∼19 200), assumed to be strongly functional, from common polymorphisms (∼35 600), assumed to be weakly functional (area under the receiver operating characteristic curve of ∼0.86). In cancer, using recurrence, multiplicity and annotation for ∼10 000 mutations in the COSMIC database, the method does well in assigning higher scores to more likely functional mutations ('drivers'). To guide experimental prioritization, we report a list of about 1000 top human cancer genes frequently mutated in one or more cancer types ranked by likely functional impact; and, an additional 1000 candidate cancer genes with rare but likely functional mutations. In addition, we estimate that at least 5% of cancer-relevant mutations involve switch of function, rather than simply loss or gain of function.

Indexed as

Genes, NeoplasmMutation, MissenseDatabases, GeneticGenes, p53GenomicsHumansNeoplasm ProteinsNeoplasmsPolymorphism, GeneticSequence AlignmentSequence Analysis, ProteinNeoplasm Proteins

Identifiers

PMID21727090
PMCPMC3177186
OpenAlexW2111326065

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.